Molecular biologist Jeff Coller joins Johns Hopkins
As a Bloomberg Distinguished Professor, he will hold appointments in the Krieger School of Arts and Sciences and the School of Medicine By Saralyn Cruickshank / Published March 16, 2021
It was during a research semester abroad in Stockholm, home of the Nobel Prize, that molecular biologist Jeff Coller discovered scientist was a viable career path for him, and it was a discovery that he calls magical.
Just a few years earlier, biologists Sidney Altman and Thomas Cech had won the Nobel Prize for their discovery that RNA a building block of cellular function can start or accelerate its own chemical processes, an ability that had only been considered possible for proteins. Coller happened to be studying a gene with this form of autocatalytic RNA, and from there it all clicked.
Published: Feb 01, 2021
FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental impairments
FINTEPLA was approved by the European Commission in December 2020 based on data from two Phase 3 studies demonstrating it safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on their existing medications
EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE)
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA
® (fenfluramine) oral solution is now available in Germany for the treatment of seizures associated with Dravet syndrome in patients aged two years and older, as an add-on therapy to existing anti-epileptic medications. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy